Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, describes toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Dr Ghorashian discusses the risks of cytokine release syndrome (CRS) as reported in the ELIANA study (NCT02435849) and the management of CRS, as well as talking on real-world data on CAR-T in B-ALL, in particular the incidence of hypogammaglobulinemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.